LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 857

Search options

  1. Article ; Online: From Black Hole Spectral Instability to Stable Observables.

    Torres, Théo

    Physical review letters

    2023  Volume 131, Issue 11, Page(s) 111401

    Abstract: The quasinormal mode spectrum of black holes is unstable under small perturbation of the potential and has observational consequences in time signals. Such signals might be experimentally difficult to observe and probing this instability will be a ... ...

    Abstract The quasinormal mode spectrum of black holes is unstable under small perturbation of the potential and has observational consequences in time signals. Such signals might be experimentally difficult to observe and probing this instability will be a technical challenge. Here, we investigate the spectral instability of time-independent data. This leads us to study the Regge poles (RPs), the counterparts to the quasinormal modes in the complex angular momentum plane. We present evidence that the RP spectrum is unstable but that not all overtones are affected equally by this instability. In addition, we reveal that behind this spectral instability lies an underlying structure. The RP spectrum is perturbed in such a way that one can still recover stable scattering quantities using the complex angular momentum approach. Overall, the study proposes a novel and complementary approach on the black hole spectral instability phenomena that allows us to reveal a surprising and unexpected mechanism at play that protects scattering quantities from the instability.
    Language English
    Publishing date 2023-09-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208853-8
    ISSN 1079-7114 ; 0031-9007
    ISSN (online) 1079-7114
    ISSN 0031-9007
    DOI 10.1103/PhysRevLett.131.111401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 4' 58/153: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Risankizumab in the Management of Psoriasis in Solid Organ Transplant Recipients.

    Luz, M / Lé, A M / Torres, T

    Actas dermo-sifiliograficas

    2024  

    Language Spanish
    Publishing date 2024-02-01
    Publishing country Spain
    Document type Case Reports
    ZDB-ID 390255-9
    ISSN 1578-2190 ; 0001-7310 ; 1138-8196
    ISSN (online) 1578-2190
    ISSN 0001-7310 ; 1138-8196
    DOI 10.1016/j.ad.2023.09.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.188: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Selective Il-23 Inhibitors: The New Kids on the Block in the Treatment of Psoriasis.

    Torres, T

    Actas dermo-sifiliograficas

    2018  Volume 109, Issue 8, Page(s) 674–676

    Title translation Inhibidores selectivos de la IL-23: los recién llegados al tratamiento de la psoriasis.
    MeSH term(s) Humans ; Interleukin-23/antagonists & inhibitors ; Psoriasis/drug therapy
    Chemical Substances Interleukin-23
    Language Spanish
    Publishing date 2018-07-02
    Document type Journal Article
    ZDB-ID 2541876-2
    ISSN 2173-5778 ; 2173-5778
    ISSN (online) 2173-5778
    ISSN 2173-5778
    DOI 10.1016/j.ad.2018.03.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Dupilumab for Atopic Dermatitis During Pregnancy and Breastfeeding: A Case Report.

    Alvarenga, J M / Maria Lé, A / Torres, T

    Actas dermo-sifiliograficas

    2023  

    Language Spanish
    Publishing date 2023-10-17
    Publishing country Spain
    Document type Case Reports
    ZDB-ID 390255-9
    ISSN 1578-2190 ; 0001-7310 ; 1138-8196
    ISSN (online) 1578-2190
    ISSN 0001-7310 ; 1138-8196
    DOI 10.1016/j.ad.2023.10.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.188: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Estimate of the superradiance spectrum in dispersive media.

    Torres, Theo

    Philosophical transactions. Series A, Mathematical, physical, and engineering sciences

    2020  Volume 378, Issue 2177, Page(s) 20190236

    Abstract: In 2016, the Nottingham group detected the rotational superradiance effect. While this experiment demonstrated the robustness of the superradiance process, it still lacks a complete theoretical description due to the many effects at stage in the ... ...

    Abstract In 2016, the Nottingham group detected the rotational superradiance effect. While this experiment demonstrated the robustness of the superradiance process, it still lacks a complete theoretical description due to the many effects at stage in the experiment. In this paper, we shine new light on this experiment by deriving an estimate of the reflection coefficient in the dispersive regime by means of a Wentzel-Kramers-Brillouin analysis. This estimate is used to evaluate the reflection coefficient spectrum of counter-rotating modes in the Nottingham experiment. Our finding suggests that the vortex flow in the superradiance experiment was not purely absorbing, contrary to the event horizon of a rotating black hole. While this result increases the gap between this experimental vortex flow and a rotating black hole, it is argued that it is in fact this gap that is the source of novel ideas. This article is part of a discussion meeting issue 'The next generation of analogue gravity experiments'.
    Language English
    Publishing date 2020-07-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 208381-4
    ISSN 1471-2962 ; 0080-4614 ; 0264-3820 ; 0264-3952 ; 1364-503X
    ISSN (online) 1471-2962
    ISSN 0080-4614 ; 0264-3820 ; 0264-3952 ; 1364-503X
    DOI 10.1098/rsta.2019.0236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 4' 46/25: Show issues
    Z PHI 2: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Oral therapies for psoriasis and psoriatic arthritis: current knowledge and future perspectives.

    Torres, Tiago

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia

    2020  Volume 155, Issue 4, Page(s) 384–385

    MeSH term(s) Administration, Oral ; Arthritis, Psoriatic/drug therapy ; Forecasting ; Humans ; Psoriasis/drug therapy
    Language English
    Publishing date 2020-06-15
    Publishing country Italy
    Document type Editorial
    ZDB-ID 604114-0
    ISSN 1827-1820 ; 0026-4741 ; 0392-0488
    ISSN (online) 1827-1820
    ISSN 0026-4741 ; 0392-0488
    DOI 10.23736/S0392-0488.20.06712-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 119: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Difamilast for the treatment of atopic dermatitis.

    Freitas, Egídio / Torres, Tiago

    The Journal of international medical research

    2023  Volume 51, Issue 6, Page(s) 3000605231169445

    Abstract: Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease. The pathogenesis of AD is complex and still not fully understood. Despite recent therapeutic developments, the current therapeutic arsenal of AD remains limited and is ... ...

    Abstract Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease. The pathogenesis of AD is complex and still not fully understood. Despite recent therapeutic developments, the current therapeutic arsenal of AD remains limited and is associated with long-term efficacy and safety issues. Therefore, new topical therapies with different mechanisms of action are required to overcome the limitations of existing treatments. Difamilast is a phosphodiesterase 4 inhibitor currently in phase 3 studies. Difamilast shows antipruritic and anti-inflammatory properties and a rapid onset of action, with significant differences in some parameters from the vehicle within 1 week of treatment. Phase 2 and 3 clinical trials have shown that difamilast ointments are effective and well tolerated in adult and pediatric patients with AD, and are expected to be used for long-term AD treatment. In 2021, difamilast was the first phosphodiesterase 4inhibitor to acquire manufacturing and marketing approval in Japan for the treatment of adult and pediatric patients (2 years of age and older) with AD. This article is a narrative review of the current literature on difamilast in the management of AD.
    MeSH term(s) Adult ; Humans ; Child ; Dermatitis, Atopic/drug therapy ; Skin ; Benzamides ; Commerce
    Chemical Substances difamilast (T3U32GLJ0F) ; Benzamides
    Language English
    Publishing date 2023-06-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 184023-x
    ISSN 1473-2300 ; 0300-0605 ; 0142-2596
    ISSN (online) 1473-2300
    ISSN 0300-0605 ; 0142-2596
    DOI 10.1177/03000605231169445
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: New molecules for atopic dermatitis treatment beyond biological therapy.

    Freitas, Egídio / Torres, Tiago

    Current opinion in allergy and clinical immunology

    2023  Volume 23, Issue 3, Page(s) 210–215

    Abstract: Purpose of review: This review aims to provide a summary of current knowledge on new topical and oral non-biological therapies recently approved for Atopic Dermatitis (AD) treatment.: Recent findings: The immense research carried out in the last ... ...

    Abstract Purpose of review: This review aims to provide a summary of current knowledge on new topical and oral non-biological therapies recently approved for Atopic Dermatitis (AD) treatment.
    Recent findings: The immense research carried out in the last decade has focused on understanding the molecular basis underlying AD and has allowed the development of new targeted drugs. Despite several biologic therapies are approved or in development, other non-biologic targeted therapies (small molecules) have emerged, such as the Janus kinase (JAK) inhibitors baricitinib, upadacitinib and abrocitinib, expanding the range of therapeutic options. Based on recent available data from head-to-head comparisons and meta-analysis studies, JAK inhibitors showed a faster onset of action and slightly higher efficacy at 16 weeks compared with biologic agents. Concerning topical treatment, presently, corticosteroids and calcineurin inhibitors are the main therapeutic options, but are not recommended for long-term management due to potential safety issues. Currently, two topical JAK inhibitors (ruxolitinib and delgocitinib) and one phosphodiesterase 4 (PDE4) inhibitor (difamilast) are approved and have shown good efficacy results and a favorable safety profile.
    Summary: These new drugs (systemic and topical) are needed to increase the success of AD treatment, particularly for patients who do not or no longer respond to treatment.
    MeSH term(s) Humans ; Dermatitis, Atopic/drug therapy ; Janus Kinase Inhibitors/therapeutic use ; Administration, Topical ; Biological Therapy ; Phosphodiesterase 4 Inhibitors/therapeutic use
    Chemical Substances Janus Kinase Inhibitors ; Phosphodiesterase 4 Inhibitors
    Language English
    Publishing date 2023-04-06
    Publishing country United States
    Document type Review ; Meta-Analysis ; Journal Article
    ZDB-ID 2088710-3
    ISSN 1473-6322 ; 1528-4050
    ISSN (online) 1473-6322
    ISSN 1528-4050
    DOI 10.1097/ACI.0000000000000910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5666: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.

    Drakos, Anastasia / Torres, Tiago / Vender, Ronald

    Pharmaceutics

    2024  Volume 16, Issue 1

    Abstract: The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials. ... ...

    Abstract The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23/IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials. These agents however are costly, are associated with a risk of immunogenicity, and require administration by intravenous or subcutaneous injection, limiting their use among patients. Oral therapies, specifically small molecule and microbiome therapeutics, have the potential to be more convenient and cost-effective agents for patients and have been a focus of development in recent years, with few targeted oral medications available for the disease. In this manuscript, we review pipeline oral therapies for psoriasis identified through a search of ClinicalTrials.gov (30 June 2022-1 October 2023). Available preclinical and clinical trial data on each therapeutic agent are discussed. Small molecules under development include tumor necrosis factor inhibitors, IL-23 inhibitors, IL-17 inhibitors, phosphodiesterase-4 inhibitors, Janus kinase inhibitors, A3 adenosine receptor agonists, and sphingosine-1-phosphate receptor 1 agonists, several of which are entering phase III trials. Oral microbials have also demonstrated success in early phase studies. As new oral therapies emerge for the treatment of psoriasis, real-world data and comparative trials are needed to better inform their use among patients.
    Language English
    Publishing date 2024-01-15
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527217-2
    ISSN 1999-4923
    ISSN 1999-4923
    DOI 10.3390/pharmaceutics16010111
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Risankizumab, a therapeutic alternative for psoriasis in people living with HIV.

    Estevinho, Tomás / Freitas, Egídio / Torres, Tiago

    The Journal of international medical research

    2024  Volume 52, Issue 3, Page(s) 3000605241229324

    Abstract: The management of psoriasis in individuals with human immunodeficiency virus (HIV) presents a unique challenge, marked by a more severe progression and limited efficacy of first- and second-line treatments. Although conventional systemic therapies might ... ...

    Abstract The management of psoriasis in individuals with human immunodeficiency virus (HIV) presents a unique challenge, marked by a more severe progression and limited efficacy of first- and second-line treatments. Although conventional systemic therapies might be considered, these agents are immunosuppressants, making their use challenging in people living with HIV (PLHIV). Biologic agents are frequently used in individuals with moderate-to-severe psoriasis, but their efficacy and safety data in PLHIV are very limited, as this patient group tends to be excluded from clinical trials. Risankizumab is a selective interleukin-23 (IL-23) inhibitor that has demonstrated a favourable safety profile and high efficacy in long-term studies and clinical practice. This current case report presents two clinical cases of PLHIV with plaque psoriasis who were effectively treated with the biologic agent risankizumab, with no reported safety issues. Although there are limited data on the use of biologics in PLHIV, this case series suggests that IL-23 inhibitors, namely risankizumab, might be a valuable therapeutic option for this population. Additional research and larger studies are needed to gain a more comprehensive understanding of the long-term safety and efficacy of IL-23 inhibitors in individuals affected by HIV.
    MeSH term(s) Humans ; HIV ; Interleukin-23 ; Psoriasis/complications ; Psoriasis/drug therapy ; HIV Infections/complications ; HIV Infections/drug therapy ; Antibodies, Monoclonal
    Chemical Substances risankizumab (90ZX3Q3FR7) ; Interleukin-23 ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-03-12
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 184023-x
    ISSN 1473-2300 ; 0300-0605 ; 0142-2596
    ISSN (online) 1473-2300
    ISSN 0300-0605 ; 0142-2596
    DOI 10.1177/03000605241229324
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top